066700 — THERAGEN ETEX CO Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapContrarian

Market Cap
KR₩123bn
Enterprise Value
KR₩155bn
Revenue
KR₩222bn

Annual income statement for THERAGEN ETEX CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	138,083	143,023	166,567	190,769	221,725
Cost of Revenue
Gross Profit	37,714	45,586	61,175	77,868	102,654
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	134,378	149,613	175,648	179,746	209,773
Operating Profit	3,705	-6,591	-9,081	11,023	11,952
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	56,001	-8,340	-12,676	13,855	33,023
Provision for Income Taxes
Net Income After Taxes	43,967	-9,079	-11,385	12,428	29,954
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	43,646	-8,968	-11,854	9,561	26,211
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	43,646	-8,968	-11,854	9,561	26,211
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,404	-278	-333	249	858
Dividends per Share